OTCMKTS:AOLS - Aeolus Pharmaceuticals Stock Price, Price Target & More

$0.0042 0.00 (-19.23 %)
(As of 04/20/2018 02:20 PM ET)
Previous Close$0.0052
Today's Range$0.0042 - $0.0042
52-Week Range$0.0010 - $0.1226
Volume100,000 shs
Average Volume199,249 shs
Market Capitalization$790,000.00
P/E RatioN/A
Dividend YieldN/A
Beta2.36

About Aeolus Pharmaceuticals (OTCMKTS:AOLS)

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Receive AOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for AOLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:AOLS
CUSIPN/A
Phone949-481-9825

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.08 million
Price / Sales0.31
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book0.21

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees4
Outstanding Shares152,090,000

How to Become a New Pot Stock Millionaire

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Frequently Asked Questions

What is Aeolus Pharmaceuticals' stock symbol?

Aeolus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "AOLS."

How were Aeolus Pharmaceuticals' earnings last quarter?

Aeolus Pharmaceuticals (OTCMKTS:AOLS) posted its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The biopharmaceutical company had revenue of $0.01 million for the quarter. View Aeolus Pharmaceuticals' Earnings History.

When is Aeolus Pharmaceuticals' next earnings date?

Aeolus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 21st 2018. View Earnings Estimates for Aeolus Pharmaceuticals.

Who are some of Aeolus Pharmaceuticals' key competitors?

Who are Aeolus Pharmaceuticals' key executives?

Aeolus Pharmaceuticals' management team includes the folowing people:
  • Mr. David C. Cavalier, Chairman, CFO & Sec. (Age 49)
  • Mr. John L. McManus, CEO & Pres (Age 54)
  • Mr. Christopher Stanley, VP of Operations
  • Dr. Brian J. Day Ph.D., Chief Scientific Officer (Age 58)

Has Aeolus Pharmaceuticals been receiving favorable news coverage?

Press coverage about AOLS stock has trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aeolus Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.41 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Aeolus Pharmaceuticals?

Shares of AOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aeolus Pharmaceuticals' stock price today?

One share of AOLS stock can currently be purchased for approximately $0.0042.

How big of a company is Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals has a market capitalization of $790,000.00 and generates $2.08 million in revenue each year. Aeolus Pharmaceuticals employs 4 workers across the globe.

How can I contact Aeolus Pharmaceuticals?

Aeolus Pharmaceuticals' mailing address is 26361 CROWN VALLEY PARKWAY SUITE 150, MISSION VIEJO CA, 92691. The biopharmaceutical company can be reached via phone at 949-481-9825 or via email at [email protected]


MarketBeat Community Rating for Aeolus Pharmaceuticals (AOLS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about Aeolus Pharmaceuticals and other stocks. Vote "Outperform" if you believe AOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 4/20/2016 forward)

Earnings

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Earnings History and Estimates Chart

Earnings by Quarter for Aeolus Pharmaceuticals (OTCMKTS:AOLS)

Aeolus Pharmaceuticals (OTCMKTS AOLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/21/2018        
8/14/2017Q3 2017($0.01)$0.01 millionViewN/AView Earnings Details
5/15/2017Q2 2017($0.01)$0.13 millionViewN/AView Earnings Details
2/17/2017Q1 2017($0.01)$0.08 millionViewN/AView Earnings Details
12/21/2016Q4 2016($0.01)$0.55 millionViewN/AView Earnings Details
8/15/2016Q3 2016($0.01)$0.66 millionViewN/AView Earnings Details
5/16/2016Q2 2016($0.02)$0.57 millionViewN/AView Earnings Details
2/16/2016Q1 2016($0.01)$0.31 millionViewN/AView Earnings Details
8/17/2015Q3 2015($0.01)$0.06 millionViewN/AView Earnings Details
5/15/2015Q2 2015($0.01)$1.19 millionViewN/AView Earnings Details
2/13/2015Q1 2015($0.01)$0.93 millionViewN/AView Earnings Details
8/15/2014Q3 2014$0.01$4.98 millionViewN/AView Earnings Details
2/14/2014Q1 2014($0.01)$0.79 millionViewN/AView Earnings Details
8/14/2013Q3 2013($0.01)$0.84 millionViewN/AView Earnings Details
5/15/2013Q2 2013($0.01)$0.86 millionViewN/AView Earnings Details
2/19/2013Q1 2013($0.07)ViewN/AView Earnings Details
1/2/2013Q4 2012$0.02($0.02)ViewN/AView Earnings Details
8/14/2012Q3 2012($0.01)($0.01)ViewN/AView Earnings Details
5/14/2012Q2 2012($0.01)($0.01)ViewN/AView Earnings Details
2/13/2012Q1 2012($0.01)ViewN/AView Earnings Details
12/27/2011Q4 2011($0.02)ViewN/AView Earnings Details
8/15/2011Q3 2011($0.01)($0.02)ViewN/AView Earnings Details
5/16/2011Q2 2011($0.01)($0.01)ViewN/AView Earnings Details
12/30/2010Q4 2010$0.01($0.03)ViewN/AView Earnings Details
8/13/2010Q3 2010($0.02)ViewN/AView Earnings Details
5/17/2010Q2 2010($0.01)ViewN/AView Earnings Details
2/19/2010Q1 2010($0.33)ViewN/AView Earnings Details
12/28/2009Q4 2009($0.02)ViewN/AView Earnings Details
7/31/2009Q3 2009($0.01)ViewN/AView Earnings Details
5/1/2009Q2 2009($0.02)ViewN/AView Earnings Details
2/6/2009Q1 2009($0.02)ViewN/AView Earnings Details
12/12/2008Q4 2008($0.05)ViewN/AView Earnings Details
8/4/2008Q3 2008($0.02)ViewN/AView Earnings Details
5/9/2008Q2 2008($0.02)ViewN/AView Earnings Details
2/6/2008Q1 2008($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aeolus Pharmaceuticals (OTCMKTS AOLS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 66.60%
Insider Trading History for Aeolus Pharmaceuticals (OTCMKTS:AOLS)

Aeolus Pharmaceuticals (OTCMKTS AOLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2013John L McmanusCEOBuy10,000$0.35$3,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aeolus Pharmaceuticals (OTCMKTS AOLS) News Headlines

Source:
DateHeadline
Aeolus Pharmaceuticals, Inc.: Aeolus Announces Commencement of Assignment for the Benefit of CreditorsAeolus Pharmaceuticals, Inc.: Aeolus Announces Commencement of Assignment for the Benefit of Creditors
www.finanznachrichten.de - March 24 at 9:43 AM
Aeolus Announces Commencement of Assignment for the Benefit of CreditorsAeolus Announces Commencement of Assignment for the Benefit of Creditors
finance.yahoo.com - March 23 at 4:39 PM
Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150
finance.yahoo.com - October 2 at 3:50 PM
Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation DamageAeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage
finance.yahoo.com - September 22 at 1:27 PM
Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy After Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in RatsAeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy After Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats
finance.yahoo.com - September 20 at 4:40 PM
AEOLUS AEOL 10150 is Safe and Well Tolerated in Phase 1 Study in Healthy SubjectsAEOLUS' AEOL 10150 is Safe and Well Tolerated in Phase 1 Study in Healthy Subjects
finance.yahoo.com - September 18 at 4:20 PM
Aeolus Pharmaceuticals Inc. (AOLS) Releases Quarterly  Earnings ResultsAeolus Pharmaceuticals Inc. (AOLS) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 16 at 10:54 AM
Aeolus Announces Third Quarter Financial Results for Fiscal Year 2017Aeolus Announces Third Quarter Financial Results for Fiscal Year 2017
finance.yahoo.com - August 14 at 9:19 PM
Aeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) to Release Quarterly Earnings on MondayAeolus Pharmaceuticals Inc. (OTCMKTS:AOLS) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - August 7 at 7:40 AM
AEOLUS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD DisclosureAEOLUS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure
biz.yahoo.com - May 26 at 12:58 PM
AEOLUS PHARMACEUTICALS, INC. Files SEC form 10-Q/A, Quarterly ReportAEOLUS PHARMACEUTICALS, INC. Files SEC form 10-Q/A, Quarterly Report
biz.yahoo.com - May 16 at 5:09 PM
AEOLUS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportAEOLUS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 16 at 6:04 AM

SEC Filings

Aeolus Pharmaceuticals (OTCMKTS:AOLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aeolus Pharmaceuticals (OTCMKTS:AOLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aeolus Pharmaceuticals (OTCMKTS AOLS) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.